Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches

被引：52
作者：
Kim, Kook Hwan [1 ]
Lee, Myung-Shik [1 ,2 ]
机构：
[1] Yonsei Univ, Severance Biomed Res Inst, Coll Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
来源：
FRONTIERS IN ENDOCRINOLOGY | 2018年 / 9卷
基金：
新加坡国家研究基金会;
关键词：
NAFLD; NASH; steatosis; inflammation; fibrosis; multiple-parallel hit; FATTY LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; GROWTH-FACTOR; 21; GLUCAGON-LIKE PEPTIDE-1; INFLAMMATORY EXTRACELLULAR VESICLES; DIFFERENTIATION FACTOR 15; HEPATIC STELLATE CELLS; ADIPOSE-TISSUE; INSULIN-RESISTANCE; GENETIC-VARIATION;
D O I：
10.3389/fendo.2018.00485
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is an emerging global health problem and a potential risk factor for type 2 diabetes, cardiovascular disease, and chronic kidney disease. Nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD, is a predisposing factor for development of cirrhosis and hepatocellular carcinoma. The increasing prevalence of NASH emphasizes the need for novel therapeutic approaches. Although therapeutic drugs against NASH are not yet available, fundamental insights into the pathogenesis of NASH have been made during the past few decades. Multiple therapeutic strategies have been developed and are currently being explored in clinical trials or preclinical testing. The pathogenesis of NASH involves multiple intracellular/extracellular events in various cell types in the liver or crosstalk events between the liver and other organs. Here, we review current findings and knowledge regarding the pathogenesis of NASH, focusing on the most recent advances. We also highlight hormone-based therapeutic approaches for treatment of NASH.
引用
收藏
页数：14
相关论文
共 146 条
  • [41] Xie L., Wang P.X., Zhang P., Zhang X.J., Zhao G.N., Wang A., Et al., DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity, J Hepatol, 65, pp. 113-124, (2016)
  • [42] Wang P.X., Ji Y.X., Zhang X.J., Zhao L.P., Yan Z.Z., Zhang P., Et al., Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Nat Med, 23, pp. 439-449, (2017)
  • [43] Zhang P., Wang P.X., Zhao L.P., Zhang X., Ji Y.X., Zhang X.J., Et al., The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis, Nat Med, 24, pp. 84-94, (2018)
  • [44] Ibrahim S.H., Hirsova P., Gores G.J., Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation, Gut, 67, pp. 963-972, (2018)
  • [45] Greuter T., Malhi H., Gores G.J., Shah V.H., Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis, JCI Insight, 2, (2017)
  • [46] Hirsova P., Gores G.J., Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis, Cell Mol Gastroenterol Hepatol, 1, pp. 17-27, (2015)
  • [47] Wree A., Broderick L., Canbay A., Hoffman H.M., Feldstein A.E., From NAFLD to NASH to cirrhosis-new insights into disease mechanisms, Nat Rev Gastroenterol Hepatol, 10, pp. 627-636, (2013)
  • [48] Povero D., Eguchi A., Niesman I.R., Andronikou N., de Mollerat du Jeu X., Mulya A., Et al., Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells, Sci Signal, 6, (2013)
  • [49] Povero D., Panera N., Eguchi A., Johnson C.D., Papouchado B.G., de Araujo Horcel L., Et al., Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-gamma, Cell Mol Gastroenterol Hepatol, 1, pp. 646-663, (2015)
  • [50] Kakazu E., Mauer A.S., Yin M., Malhi H., Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1alpha-dependent manner, J Lipid Res, 57, pp. 233-245, (2016)
12345678910